Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an announcement.
RemeGen Co., Ltd. has approved a cash management strategy allowing the use of up to RMB2.5 billion in idle self-owned funds to purchase wealth management products, as part of efforts to optimize returns on surplus liquidity. The company recently expanded its deployment with Huatai Securities Co. (HTSC), entering a series of wealth management product agreements totaling RMB488 million, including two new purchases of RMB15 million and RMB20 million.
Because these six HTSC transactions were conducted with the same financial institution within 12 months and are of a similar nature, they must be aggregated under Hong Kong Listing Rules for compliance purposes. The aggregated size pushes one of the applicable percentage ratios above 5% but below 25%, classifying the purchases as a discloseable transaction that triggers reporting and announcement requirements, signaling active treasury management without reaching a major transaction threshold.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China, listed in Hong Kong under stock code 9995. The company operates in the healthcare and life sciences sector, focusing on the development and commercialization of innovative biologic drugs and therapies for unmet medical needs in domestic and international markets.
Average Trading Volume: 4,190,666
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.14B
For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.